- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Gilead Sciences Inc
+ Add to WatchlistGILD:US
55.9300 USD 0.5400 0.96%As of 20:10:00 ET on 05/22/2013.
Snapshot for Gilead Sciences Inc (GILD)
| Open: | 57.0000 | Day's Range: | 55.6200 - 58.0650 | Volume: | 12,767,258 |
|---|---|---|---|---|---|
| Previous Close: | 55.9300 | 52wk Range: | 24.1200 - 58.0650 | 1-Yr Rtn: | +122.83% |
Key Statistics for GILD
| Current P/E Ratio (ttm) | 30.6765 |
|---|---|
| Estimated P/E(12/2013) | 27.9092 |
| Relative P/E vs. SPX | 1.8986 |
| Earnings Per Share (USD) (ttm) | 1.8232 |
| Est. EPS (USD) (12/2013) | 2.0040 |
| Est. PEG Ratio | 1.0739 |
| Market Cap (M USD) | 85,313.15 |
| Shares Outstanding (M) | 1,525.36 |
| 30 Day Average Volume | 13,455,157 |
| Price/Book (mrq) | 8.3980 |
| Price/Sale (ttm) | 8.5250 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/26/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for GILD
Company Profile & Key Executives for GILD
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
| John C MartinChairman/CEO | John F MilliganPresident/COO |
| Norbert W BischofbergerExec VP:Research & Development | Kevin YoungExec VP:Commercial Operations |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
GILD News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page